Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Fabrizio Cantini, Corrado Blandizzi, Laura Niccoli, Linda Petrone & Delia Goletti. (2020) Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opinion on Drug Safety 19:7, pages 861-872.
Read now
Read now
Maria Alexandra Rodrigues & Tiago Torres. (2020) JAK/STAT inhibitors for the treatment of atopic dermatitis. Journal of Dermatological Treatment 31:1, pages 33-40.
Read now
Read now
Paweł Kawalec, Katarzyna Śladowska, Iwona Malinowska-Lipień, Tomasz Brzostek & Maria Kózka. (2019) New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib. Therapeutics and Clinical Risk Management 15, pages 275-284.
Read now
Read now
Jing Wu, Zhaohua Zhu, Qinghong Yu & Changhai Ding. (2019) Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to Ⅱ clinical trials. Expert Opinion on Investigational Drugs 28:12, pages 1113-1123.
Read now
Read now
Satoshi Kubo, Shingo Nakayamada & Yoshiya Tanaka. (2019) Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. Expert Review of Clinical Immunology 15:7, pages 693-700.
Read now
Read now
Articles from other publishers (27)
Victor Yang, Tue W. Kragstrup, Christopher McMaster, Pankti Reid, Namrata Singh, Stine R. Haysen, Philip C. Robinson & David F. L. Liew. (2023) Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors. Drug Safety 46:11, pages 1049-1071.
Crossref
Crossref
Chrysoula G. Gialouri, Savvina Moustafa, Konstantinos Thomas, Emilia Hadziyannis & Dimitrios Vassilopoulos. (2023) Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatology International 43:3, pages 421-435.
Crossref
Crossref
Carmen Olga Sánchez González & Juan Carlos Nieto González. (2022) JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature. Reumatología Clínica (English Edition) 18:8, pages 453-458.
Crossref
Crossref
Carmen Olga Sánchez González & Juan Carlos Nieto González. (2022) Inhibidores de receptores JAK quinasa e infección por virus varicela zoster en pacientes con artritis reumatoide. Revisión sistemática de la literatura. Reumatología Clínica 18:8, pages 453-458.
Crossref
Crossref
Matthew J Koster, Cynthia S Crowson, Rachel E Giblon, Jane M Jaquith, Ali Duarte-García, Eric L Matteson, Cornelia M Weyand & Kenneth J Warrington. (2022) Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Annals of the Rheumatic Diseases 81:6, pages 861-867.
Crossref
Crossref
Christopher Cerda-Contreras, Laura Nuzzolo-Shihadeh, Adrián Camacho-Ortiz & Eduardo Perez-Alba. (2021) Baricitinib as Treatment for Coronavirus Disease 2019 (COVID-19): Friend or Foe of the Pancreas?. Clinical Infectious Diseases 73:11, pages e3977-e3978.
Crossref
Crossref
Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka, Motohiro Oribe, Mitsuhiro Kawano, Masayuki Yokoyama, Aileen L. Pangan, Yuko Konishi, Sebastian Meerwein & Yoshiya Tanaka. (2021) Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Research & Therapy 23:1.
Crossref
Crossref
Maria M. Crespo, Tamara Claridge, Robyn T. Domsic, Matthew Hartwig, Jasleen Kukreja, Kathleen Stratton, Kevin M. Chan, Maria Molina, Patricia Ging, Adam Cochrane, Konrad Hoetzenecker, Usman Ahmad, Siddhartha Kapnadak, Irina Timofte, Geert Verleden, Dennis Lyu, Sana Quddus, Nicole Davis, Mary Porteous, Jorge Mallea, Michael Perch, Olivier Distler, Kristin Highland, Jesper Magnusson, Robin Vos & Allan R. Glanville. (2021) ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements. The Journal of Heart and Lung Transplantation 40:11, pages 1279-1300.
Crossref
Crossref
Jawad Bilal, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Sandipan Bhattacharjee, Michelle R. Obert, Maryam Sadiq, Mohamed A. Abd El Aziz, Yahya Nomaan, Lary J. Prokop, Long Ge, Mohammad H. Murad, Alan H. Bryce, Robert D. McBane & C. Kent Kwoh. (2021) Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis. Mayo Clinic Proceedings 96:7, pages 1861-1873.
Crossref
Crossref
Philip G. Conaghan, Eduardo Mysler, Yoshiya Tanaka, Barbara Da Silva-Tillmann, Tim Shaw, John Liu, Ryan Ferguson, Jeffrey V. Enejosa, Stanley Cohen, Peter Nash, William Rigby & Gerd Burmester. (2021) Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program. Drug Safety 44:5, pages 515-530.
Crossref
Crossref
Ivan Urits, Jacob Israel, Hayk Hakobyan, George Yusin, Grace Lassiter, Nathan Fackler, Amnon A. Berger, Hisham Kassem, Alan Kaye & Omar Viswanath. (2020) Baricitinib for the treatment of rheumatoid arthritis. Rheumatology 58:6, pages 407-415.
Crossref
Crossref
Nobunori Takahashi, Shuji Asai, Tomonori Kobayakawa, Atsushi Kaneko, Tatsuo Watanabe, Takefumi Kato, Tsuyoshi Nishiume, Hisato Ishikawa, Yutaka Yoshioka, Yasuhide Kanayama, Tsuyoshi Watanabe, Yuji Hirano, Masahiro Hanabayashi, Yuichiro Yabe, Yutaka Yokota, Mochihito Suzuki, Yasumori Sobue, Kenya Terabe, Naoki Ishiguro & Toshihisa Kojima. (2020) Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry. Scientific Reports 10:1.
Crossref
Crossref
Jun K Khoo, Hayley Barnes, Seraphina Key, Ian N Glaspole & Andrew J Östör. (2020) Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis. Rheumatology 59:9, pages 2217-2225.
Crossref
Crossref
Roy Fleischmann, Tsutomu Takeuchi, Michael Schiff, Douglas Schlichting, Li Xie, Maher Issa, Ivaylo Stoykov, Jeffrey Lisse, Pindaro Martinez‐Osuna, Terence Rooney & Cristiano A. F. Zerbini. (2020) Efficacy and Safety of Long‐Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate. Arthritis Care & Research 72:8, pages 1112-1121.
Crossref
Crossref
Jacopo Angelini, Rossella Talotta, Rossana Roncato, Giulia Fornasier, Giorgia Barbiero, Lisa Dal Cin, Serena Brancati & Francesco Scaglione. (2020) JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future. Biomolecules 10:7, pages 1002.
Crossref
Crossref
Joshua S. Davis, David Ferreira, Emma Paige, Craig Gedye & Michael Boyle. (2020) Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clinical Microbiology Reviews 33:3.
Crossref
Crossref
Alexandre Sepriano, Andreas Kerschbaumer, Josef S Smolen, Désirée van der Heijde, Maxime Dougados, Ronald van Vollenhoven, Iain B McInnes, Johannes W Bijlsma, Gerd R Burmester, Maarten de Wit, Louise Falzon & Robert Landewé. (2020) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases 79:6, pages 760-770.
Crossref
Crossref
Pablo A. Olivera, Juan S. Lasa, Stefanos Bonovas, Silvio Danese & Laurent Peyrin-Biroulet. (2020) Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. Gastroenterology 158:6, pages 1554-1573.e12.
Crossref
Crossref
Flavia Sunzini, Iain McInnes & Stefan Siebert. (2020) JAK inhibitors and infections risk: focus on herpes zoster. Therapeutic Advances in Musculoskeletal Disease 12, pages 1759720X2093605.
Crossref
Crossref
Chengfeng Qiu, Xiang Zhao, Lang She, Zhihua Shi, Ziwei Deng, Liming Tan, Xiaojun Tu, Shilong Jiang & Bin Tang. (2019) Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Lipids in Health and Disease 18:1.
Crossref
Crossref
Yoshiya Tanaka, Tsutomu Takeuchi, Sakae Tanaka, Atsushi Kawakami, Manabu Iwasaki, Yeong Wook Song, Yi-Hsing Chen, James Cheng-Chung Wei, Sang-Heon Lee, Mitsuhiro Rokuda, Hiroyuki Izutsu, Satoshi Ushijima, Yuichiro Kaneko, Rio Akazawa, Teruaki Shiomi & Emi Yamada. (2019) Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid
arthritis and an inadequate response to conventional DMARDs: a randomised,
double-blind, placebo-controlled phase III trial (RAJ3). Annals of the Rheumatic Diseases 78:10, pages 1320-1332.
Crossref
Crossref
Victoria Furer, Christien Rondaan, Marloes Heijstek, Sander van Assen, Marc Bijl, Nancy Agmon-Levin, Ferdinand C Breedveld, Raffaele D'Amelio, Maxime Dougados, Meliha Crnkic Kapetanovic, Jacob M van Laar, Annette Ladefoged de Thurah, Robert Landewé, Anna Molto, Ulf Müller-Ladner, Karen Schreiber, Leo Smolar, Jim Walker, Klaus Warnatz, Nico M Wulffraat & Ori Elkayam. (2019) Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open 5:2, pages e001041.
Crossref
Crossref
Yuya Fujita, Masao Nawata, Atsushi Nagayasu, Kazuki Someya, Kazuyoshi Saito & Yoshiya Tanaka. (2019) Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report. Case Reports in Rheumatology 2019, pages 1-5.
Crossref
Crossref
Helen He & Emma Guttman-Yassky. (2018) JAK Inhibitors for Atopic Dermatitis: An Update. American Journal of Clinical Dermatology 20:2, pages 181-192.
Crossref
Crossref
Sumit Kunwar, Christopher E. Collins & Florina Constantinescu. (2018) Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Clinical Rheumatology 37:10, pages 2611-2620.
Crossref
Crossref
Zhi‑Peng Wu, Pei Zhang, Jian‑Zhong Bai, Yuan Liang, Jin‑Shan He & Jing‑Cheng Wang. (2018) Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease‑modifying anti‑rheumatic drugs: A meta‑analysis of randomized controlled trials. Experimental and Therapeutic Medicine.
Crossref
Crossref
Zaina T. Al-Salama & Lesley J. Scott. (2018) Baricitinib: A Review in Rheumatoid Arthritis. Drugs 78:7, pages 761-772.
Crossref
Crossref